This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Prognostic importance of BNP (B-type natriuretic peptide) and effect of Empagliflozin in the EMPEROR - Reduced Trial

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Prognostic Importance of BNP (B-type natriuretic peptide) and Effect of Empagliflozin in the EMPEROR-Reduced Trial

Among patients affected by heart failure (HF) with reduced ejection fraction (HFrEF), elevated concentrations of N-terminal pro-B-type natriuretic peptide (NT-proBNP) are associated with more severe symptoms, worse health status, and a higher risk for hospitalization for HF or cardiovascular (CV) death (1)

  • showed that with respect to the application of guideline directed medical therapy (GDMT)
    • in patients with HFrEF, those with decrease in NT-proBNP <=1000 pg/mL during GDMT had better outcomes

In a pre-specified analysis using data of the EMPEROR-Reduced trial, it was examined (2):

  • whether baseline NT-proBNP had an effect on the efficacy of SGLT2 inhibitors in HFrEF
  • what the effect of SGLT2 inhibitors was on levels of NT-proBNP,
  • whether changes in NT-proBNP after SGLT2i treatment were associated with subsequent outcomes

Study results (2):

  • treatment with empagliflozin reduced time to first events of CV death, hospitalization or the composite of both events across NT-proBNP quartiles without interaction with baseline NT-proBNP (P trend >0.05)
  • use of empagliflozin reduced the risk of total hospitalizations for HF in all NT-proBNP quartiles, with no heterogeneity between groups (Ptrend=0.49). Similar results were seen for all-cause mortality
  • patients had a lower risk of the primary endpoint of CV death/HF hospitalization if they had NT-proBNP of <1,115 pg/mL at week 12, regardless of baseline value of NT-proBNP
  • in an adjusted model, treatment with empagliflozin resulted in a 27% (95%CI: 5.6-52.6) higher likelihood of having NT-proBNP of <1,115 pg/mL (P=0.01).
    • in those with an NT-proBNP of >= 1,115 pg/mL at baseline, treatment with empagliflozin resulted in an adjusted 35% (95CI: 17-56) higher likelihood of achieving an NT-proBNP of <1,115 pg/mL compared to the placebo group (P<0.001)

The study authors concluded (2):

  • in EMPEROR-Reduced, higher baseline NT-proBNP concentrations were associated with greater risk for adverse heart failure or renal outcomes, but empagliflozin reduced risk regardless of baseline NT-proBNP concentration
  • the NT-proBNP concentration after treatment with empagliflozin better informs subsequent prognosis than pretreatment concentrations

Reference:


Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.